ALK

Celebrating the past and future of allergy solutions for life

Read about ALK's 100-year history

Pioneers in helping people with allergies

For 100 years, ALK has consistently devised and developed major advances for the treatment of allergy

Watch the video

News

See all

Post date
11/15/2023

Nine-month interim report (Q3) 2023

Read more
Post date
11/09/2023

Release date of nine-month interim report (Q3) 2023 for ALK and audio cast

Read more
Post date
10/11/2023

Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children

Read more
Post date
08/24/2023

Six-month interim report (Q2) 2023

Read more
Post date
08/18/2023

Release date of six-month interim report (Q2) 2023 for ALK and audio cast

Read more
Post date
06/19/2023

President & CEO Carsten Hellmann to step down end 2023. Peter Halling appointed as his successor

Read more
Post date
05/09/2023

Three-month interim report (Q1) 2023

Read more
Post date
05/01/2023

Release date of three-month interim report (Q1) 2023 for ALK and audio cast

Read more
Post date
04/17/2023

ALK announces preliminary Q1 figures and confirms its full-year revenue and earnings outlook

Read more

100 Years of Pioneering Allergy Solutions

A new book has been written about ALK’s fascinating development in the field of allergy

Read now

The hunt for a vaccine – a podcast in five episodes

A fascinating story about ALK and the company’s 100 years of hunting allergy vaccines have been turned into a captivating podcast.

Listen to the podcast here

Investigator-initiated clinical trials in allergy immunotherapy

The call for applications is now open!

Strategy update: Focus areas during 2021-23

Having made the necessary, significant investments to transform ALK, we are now entering the next phase of the company’s development, where we must carefully work to sustain long-term growth, while also returning ALK to profitability.

ALK in brief

Allergy at a glance

Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.

Our solutions

By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.